Vertex Pharmaceuticals Inc. (VRTX)

173.59
1.18 0.68
NASDAQ : Health Technology
Prev Close 172.41
Open 172.32
Day Low/High 172.32 / 175.25
52 Wk Low/High 151.80 / 195.81
Volume 541.37K
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 257.04M
Market Cap 43.75B
EPS 8.20
P/E Ratio 19.93
Div & Yield N.A. (N.A)
3 Drugs Stocks Pushing Industry Growth

3 Drugs Stocks Pushing Industry Growth

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a post-market leader candidate

Vertex Reports Second Quarter 2015 Financial Results

Vertex Reports Second Quarter 2015 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2015.

Apple's Earnings Could Coincide with an Overbought Reading

I’ll keep you posted as we get closer.

Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today

Vertex Pharmaceuticals (VRTX) Is Strong On High Volume Today

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a strong on high relative volume candidate

Vertex To Announce Second Quarter 2015 Financial Results On July 29

Vertex To Announce Second Quarter 2015 Financial Results On July 29

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2015 financial results on Wednesday, July 29, 2015 after the financial markets close.

Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

Vertex Pharmaceuticals (VRTX) Is Today's Unusual Social Activity Stock

Vertex Pharmaceuticals (VRTX) Is Today's Unusual Social Activity Stock

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as an unusual social activity candidate

Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

Vertex Pharmaceuticals Becomes #232 Most Shorted S&P 500 Component, Replacing Exxon Mobil

Vertex Pharmaceuticals Becomes #232 Most Shorted S&P 500 Component, Replacing Exxon Mobil

The most recent short interest data has been released by the NASDAQ for the 06/15/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as a post-market leader candidate

3 Stocks Raising The Health Care Sector Higher

3 Stocks Raising The Health Care Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors

Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N.

Vertex Announces Data Presentations At European Cystic Fibrosis Society (ECFS) Conference

Vertex Announces Data Presentations At European Cystic Fibrosis Society (ECFS) Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from PROGRESS, the long-term extension study of the investigational regimen ORKAMBI™ (lumacaftor/ivacaftor).

Vertex And Parion Sciences Establish Collaboration To Develop Epithelial Sodium Channel (ENaC) Inhibitors In Cystic Fibrosis And Other Pulmonary Diseases

Vertex And Parion Sciences Establish Collaboration To Develop Epithelial Sodium Channel (ENaC) Inhibitors In Cystic Fibrosis And Other Pulmonary Diseases

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Parion Sciences today announced that the companies will collaborate to develop investigational epithelial sodium channel (ENaC) inhibitors for the potential...

Vertex To Present At The Goldman Sachs Healthcare Conference On June 11

Vertex To Present At The Goldman Sachs Healthcare Conference On June 11

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 11 th at...

Corbus Focused on Research and in No Hurry for Partnerships, Says CEO

Corbus Focused on Research and in No Hurry for Partnerships, Says CEO

The biotech is well along in the development of a promising cystic fibrosis drug Resunab.

Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO

Corbus Ready to Take Cystic Fibrosis Drug the Distance Says CEO

It’s been a hot M&A market for biotech companies developing treatments for rare diseases.

Can Biotechs' Relative Strength Be Trusted? 6 Stocks to Watch

Sector may not be as bulletproof as we thought.

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care.

10 S&P 500 Companies to Have the Most Revenue Growth in 2015

10 S&P 500 Companies to Have the Most Revenue Growth in 2015

The top 10 list is overwhelmingly weighted toward the health care sector, with seven companies in the biotech or pharmaceuticals industries.

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest

The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a scheduled Tuesday presentation at a health care investor conference.

New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation

New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the  New England Journal of Medicine (NEJM) published data from the two Phase 3 studies of ORKAMBI TM (lumacaftor/ivacaftor), an...

Vertex To Present At The UBS Healthcare Conference On May 19

Vertex To Present At The UBS Healthcare Conference On May 19

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden, M.

Vertex Pharmaceuticals (VRTX) Stock Climbs Following FDA Advisory Panel Aprroval

Vertex Pharmaceuticals (VRTX) Stock Climbs Following FDA Advisory Panel Aprroval

Vertex Pharmaceuticals (VRTX) shares are climbing after an FDA panel gave its backing to its experimental cystic fibrosis drug Orkambi.

Cramer: I Like Receptos and Radius, as Well as the Four Horsemen

Cramer: I Like Receptos and Radius, as Well as the Four Horsemen

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

Vertex Pharmaceuticals (VRTX) Showing Unusual Social Activity Today

Vertex Pharmaceuticals (VRTX) Showing Unusual Social Activity Today

Trade-Ideas LLC identified Vertex Pharmaceuticals (VRTX) as an unusual social activity candidate

Picasso Painting Sells for a Record $179 Million Dollars at Auction

Picasso Painting Sells for a Record $179 Million Dollars at Auction

A Picasso Painting Fetched $179 million dollars at an auction at Christie's Monday night, the most ever paid for a work of art at auction.

TheStreet Quant Rating: B (Buy)